Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Sep;66(3):329-35.
doi: 10.1203/PDR.0b013e3181b24e94.

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

Priya S Kishnani  1 , Deya Corzo, Nancy D Leslie, Daniel Gruskin, Ans Van der Ploeg, John P Clancy, Rosella Parini, Gilles Morin, Michael Beck, Mislen S Bauer, Mikael Jokic, Chen-En Tsai, Brian W H Tsai, Claire Morgan, Tara O'Meara, Susan Richards, Elisa C Tsao, Hanna Mandel
Affiliations
Randomized Controlled Trial

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

Priya S Kishnani et al. Pediatr Res. 2009 Sep.

Abstract

In a previous 52-wk trial, treatment with alglucosidase alpha markedly improved cardiomyopathy, ventilatory function, and overall survival among 18 children <7 mo old with infantile-onset Pompe disease. Sixteen of the 18 patients enrolled in an extension study, where they continued to receive alglucosidase alpha at either 20 mg/kg biweekly (n = 8) or 40 mg/kg biweekly (n = 8), for up to a total of 3 y. These children continued to exhibit the benefits of alglucosidase alpha at the age of 36 mo. Cox regression analyses showed that over the entire study period, alglucosidase alpha treatment reduced the risk of death by 95%, reduced the risk of invasive ventilation or death by 91%, and reduced the risk of any type of ventilation or death by 87%, compared with an untreated historical control group. Cardiomyopathy continued to improve and 11 patients learned and sustained substantial motor skills. No significant differences in either safety or efficacy parameters were observed between the 20 and 40 mg/kg biweekly doses. Overall, long-term alglucosidase alpha treatment markedly extended survival as well as ventilation-free survival and improved cardiomyopathy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Disposition of patients in 20 mg/kg qow and 40 mg/kg qow groups.
Figure 2
Figure 2
Kaplan-Meier analyses of survival, survival free of invasive ventilation, and survival free of any ventilation. In each panel, thick solid lines show the Kaplan-Meier estimates for the treated patient group; thin solid lines show those for the historical control group, with 95% confidence intervals given by the corresponding dashed lines. Solid circles indicate right-censored observations. (A) Kaplan-Meier estimate of time from date of birth to death. Seven patients were right-censored from this analysis because they had not reached age 36 months by the end of the study, although they remained alive at that time. (B) Kaplan-Meier estimate of time from birth to invasive ventilator use or death. Four patients were right-censored from this analysis because they had not reached age 36 months by the end of the study, although they remained free of invasive ventilation that time. (C) Kaplan-Meier estimate of time from birth to any ventilator use or death. Four patients were right-censored from this analysis because they had not reached age 36 months by the end of the study, although they remained free of any ventilation that time. *Asterisk indicates that 1 patient from the historical control group remained alive at 36 months of age; this patient died at age 44 months.
Figure 3
Figure 3
Mean left ventricular mass Z-scores of treated patients from baseline to week 52; vertical bars represent standard error.
See this image and copyright information in PMC

References

    1. Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8. McGraw Hill; New York: 2001. pp. 3389–3420.
    1. Koeberl DD, Kishnani PS, Chen YT. Glycogen storage disease types I and II: treatment updates. J Inherit Metab Dis. 2007;30:159–164. - PMC - PubMed
    1. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr. 2004;144:S35–S43. - PubMed
    1. Chen YT, Amalfitano A. Towards a molecular therapy for glycogen storage disease type II (Pompe disease) Mol Med Today. 2000;6:245–251. - PubMed
    1. van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, Loonen MC, de Klerk JB, Reuser AJ, van der Ploeg AT. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112:332–340. - PubMed

Publication types